Celyad Oncology

In late 2022, Celyad Oncology implemented a significant strategic shift, dubbed "Celyad 2.0", moving away from clinical development to concentrate on research and the monetization of its intellectual property (IP) estate. This led to the discontinuation of its remaining clinical programs, including the CYAD-211 candidate for multiple myeloma. The company's current business model centers on licensing its patent portfolio related to allogeneic CAR T-cell therapies and NKG2D-based treatments to external partners. Concurrently, its research efforts are focused on advancing its differentiated platforms, such as a multiplex shRNA platform for modulating multiple genes, developing next-generation dual CARs, and exploring B7-H6-targeting immunotherapies.

Financially, the company has undergone significant restructuring to reduce operational costs, including delisting its American Depositary Shares from the Nasdaq market in May 2023 to remain solely on Euronext Brussels. The company has been exploring strategic alternatives, including asset sales, partnerships, and potential mergers, to manage its limited cash resources. In August 2025, Celyad announced the discontinuation of its R&D activities and a significant workforce reduction to focus on managing and licensing its IP portfolio.